Ana Limerick

Ms. Ana Limerick


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Cells
Verified
Journal Article
Open access
PDF file
ALAna Limerick
Ana Limerick
EMEllie A. McCabe
Ellie A. McCabe
JTJacob S. Turner
Jacob S. Turner
KKKevin Kuang
Kevin Kuang
DBDavid Brautigan
David Brautigan
ZFZheng Fu
Zheng Fu
Mutations in human CILK1 (ciliogenesis associated kinase 1) are linked to ciliopathies and epilepsy. Homozygous point and nonsense mutations that extinguish kinase activity impair primary cilia function, whereas mutations outside the kinase domain are not well understood. Here, we produced a knock-in mouse equivalent to the human CILK1 A615T variant identified in juvenile myoclonic epilepsy (JME). This residue is in the intrinsically disordered C-terminal region of CILK1 separate from the kinase domain. Mouse embryo fibroblasts (MEFs) with either heterozygous or homozygous A612T mutant alleles exhibited a higher ciliation rate, shorter individual cilia, and upregulation of ciliary Hedgehog signaling. Thus, a single A612T mutant allele was sufficient to impair primary cilia and ciliary signaling in MEFs. Gene expression profiles of wild-type versus mutant MEFs revealed profound changes in cilia-related molecular functions and biological processes. The CILK1 A615T mutant protein was not increased to the same level as the wild-type protein when co-expressed with scaffold protein KATNIP (katanin-interacting protein). Our data show that KATNIP regulation of a JME-associated single-residue variant of CILK1 is compromised, and this impairs the maintenance of primary cilia and Hedgehog signaling.

14 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SFSean H. Fu
Sean H. Fu
ALAna Limerick
Ana Limerick
CPChelsea Park
Chelsea Park
NSNiyathi Shah
Niyathi Shah
YZYing Zhang
Ying Zhang
ZFZheng Fu
Zheng Fu
The primary cilium, the cell’s sensory and signaling antenna, is a dynamic cellular organelle during the cell cycle. It is resorbed before cells enter mitosis and reformed after cells exit mitosis, and as such acts as a structural barrier to mitosis. Cancer cells that undergo rapid cell cycle and replication have a low ciliation rate. Therefore, promoting cilia formation and elongation and thereby reducing their rates of retraction hold the key to blocking cell entry into mitosis and slowing down cancer cell replication. To perform a comprehensive and efficient literature search on drugs that can promote ciliogenesis, we developed an intelligent process that integrates the GPT-3.5 application programming interface (API) into a PubMed scraper that we coded, enabling the large language model (LLM) to directly query articles for predefined user questions. Among the top candidates identified are two FDA-approved drugs, Alvocidib and Alisertib, that showed strong potential to induce cilia formation and elongation. We first confirmed that these drugs can effectively increase the ciliation rate and the cilia length of DAOY medulloblastoma cells. We then applied Alvocidib and Alisertib individually or in combination to DAOY medulloblastoma and A549 lung cancer cells and observed a statistically significant decrease in the number of viable cells. These results demonstrated the potential of using cilia-promoting drugs to suppress cancer cell replication. Additionally, it shows the massive benefits of integrating accessible large language models to conduct sweeping, rapid, and accurate literature searches.